Demographics, Serostatus, and Vaccinations for the Total Study Population and the Subsample of Participants With Pre- and Postvaccination Antibody Measurements
| . | Study Population, Median (IQR) or No. (%) . | ||
|---|---|---|---|
| Characteristic . | Total (n = 192) . | Pre- and Post-vaccine Antibody Results (n = 99)a . | Post-booster Antibody Results (n = 34) . |
| Age, y | 37 (32–44) | 38 (32–46) | 40 (35–47) |
| Female sex | 131 (68) | 65 (66) | 21 (62) |
| Race/ethnicity | |||
| Non-Hispanic and Black | 4 (2) | 3 (3) | 0 (0) |
| Non-Hispanic and Asian | 9 (5) | 4 (4) | 2 (6) |
| Non-Hispanic and White | 127 (66) | 63 (64) | 22 (64) |
| Non-Hispanic and other, ≥2 races, or unidentified | 10 (5) | 9 (9) | 3 (9) |
| Hispanic ethnicity of any race | 10 (5) | 4 (4) | 1 (3) |
| Other ethnicity of any race | 12 (6) | 4 (4) | 4 (12) |
| Unidentified ethnicity of any race | 5 (3) | 3 (3) | 1 (3) |
| Unidentified race and ethnicity | 15 (8) | 11 (9) | 1 (3) |
| Total Ig antibody serostatus before vaccination | |||
| Seronegative | 182 (95) | 93 (92) | 30 (88) |
| Seropositive | 10 (5) | 6 (6) | 4 (12) |
| At baseline visit | 5 (3) | 4 (4) | 3 (9) |
| Occurred during follow-up | 5 (3) | 2 (2) | 1 (3) |
| Vaccinations received | |||
| None | 1 (0.5) | NA | NA |
| 2 doses | 140 (73) | 50 (51) | NA |
| 3 doses | 51 (27) | 49 (49) | 34 (100) |
| . | Study Population, Median (IQR) or No. (%) . | ||
|---|---|---|---|
| Characteristic . | Total (n = 192) . | Pre- and Post-vaccine Antibody Results (n = 99)a . | Post-booster Antibody Results (n = 34) . |
| Age, y | 37 (32–44) | 38 (32–46) | 40 (35–47) |
| Female sex | 131 (68) | 65 (66) | 21 (62) |
| Race/ethnicity | |||
| Non-Hispanic and Black | 4 (2) | 3 (3) | 0 (0) |
| Non-Hispanic and Asian | 9 (5) | 4 (4) | 2 (6) |
| Non-Hispanic and White | 127 (66) | 63 (64) | 22 (64) |
| Non-Hispanic and other, ≥2 races, or unidentified | 10 (5) | 9 (9) | 3 (9) |
| Hispanic ethnicity of any race | 10 (5) | 4 (4) | 1 (3) |
| Other ethnicity of any race | 12 (6) | 4 (4) | 4 (12) |
| Unidentified ethnicity of any race | 5 (3) | 3 (3) | 1 (3) |
| Unidentified race and ethnicity | 15 (8) | 11 (9) | 1 (3) |
| Total Ig antibody serostatus before vaccination | |||
| Seronegative | 182 (95) | 93 (92) | 30 (88) |
| Seropositive | 10 (5) | 6 (6) | 4 (12) |
| At baseline visit | 5 (3) | 4 (4) | 3 (9) |
| Occurred during follow-up | 5 (3) | 2 (2) | 1 (3) |
| Vaccinations received | |||
| None | 1 (0.5) | NA | NA |
| 2 doses | 140 (73) | 50 (51) | NA |
| 3 doses | 51 (27) | 49 (49) | 34 (100) |
Abbreviations: Ig, immunoglobulin; NA, not applicable.
aPost-vaccine: after at least 1 dose.
Demographics, Serostatus, and Vaccinations for the Total Study Population and the Subsample of Participants With Pre- and Postvaccination Antibody Measurements
| . | Study Population, Median (IQR) or No. (%) . | ||
|---|---|---|---|
| Characteristic . | Total (n = 192) . | Pre- and Post-vaccine Antibody Results (n = 99)a . | Post-booster Antibody Results (n = 34) . |
| Age, y | 37 (32–44) | 38 (32–46) | 40 (35–47) |
| Female sex | 131 (68) | 65 (66) | 21 (62) |
| Race/ethnicity | |||
| Non-Hispanic and Black | 4 (2) | 3 (3) | 0 (0) |
| Non-Hispanic and Asian | 9 (5) | 4 (4) | 2 (6) |
| Non-Hispanic and White | 127 (66) | 63 (64) | 22 (64) |
| Non-Hispanic and other, ≥2 races, or unidentified | 10 (5) | 9 (9) | 3 (9) |
| Hispanic ethnicity of any race | 10 (5) | 4 (4) | 1 (3) |
| Other ethnicity of any race | 12 (6) | 4 (4) | 4 (12) |
| Unidentified ethnicity of any race | 5 (3) | 3 (3) | 1 (3) |
| Unidentified race and ethnicity | 15 (8) | 11 (9) | 1 (3) |
| Total Ig antibody serostatus before vaccination | |||
| Seronegative | 182 (95) | 93 (92) | 30 (88) |
| Seropositive | 10 (5) | 6 (6) | 4 (12) |
| At baseline visit | 5 (3) | 4 (4) | 3 (9) |
| Occurred during follow-up | 5 (3) | 2 (2) | 1 (3) |
| Vaccinations received | |||
| None | 1 (0.5) | NA | NA |
| 2 doses | 140 (73) | 50 (51) | NA |
| 3 doses | 51 (27) | 49 (49) | 34 (100) |
| . | Study Population, Median (IQR) or No. (%) . | ||
|---|---|---|---|
| Characteristic . | Total (n = 192) . | Pre- and Post-vaccine Antibody Results (n = 99)a . | Post-booster Antibody Results (n = 34) . |
| Age, y | 37 (32–44) | 38 (32–46) | 40 (35–47) |
| Female sex | 131 (68) | 65 (66) | 21 (62) |
| Race/ethnicity | |||
| Non-Hispanic and Black | 4 (2) | 3 (3) | 0 (0) |
| Non-Hispanic and Asian | 9 (5) | 4 (4) | 2 (6) |
| Non-Hispanic and White | 127 (66) | 63 (64) | 22 (64) |
| Non-Hispanic and other, ≥2 races, or unidentified | 10 (5) | 9 (9) | 3 (9) |
| Hispanic ethnicity of any race | 10 (5) | 4 (4) | 1 (3) |
| Other ethnicity of any race | 12 (6) | 4 (4) | 4 (12) |
| Unidentified ethnicity of any race | 5 (3) | 3 (3) | 1 (3) |
| Unidentified race and ethnicity | 15 (8) | 11 (9) | 1 (3) |
| Total Ig antibody serostatus before vaccination | |||
| Seronegative | 182 (95) | 93 (92) | 30 (88) |
| Seropositive | 10 (5) | 6 (6) | 4 (12) |
| At baseline visit | 5 (3) | 4 (4) | 3 (9) |
| Occurred during follow-up | 5 (3) | 2 (2) | 1 (3) |
| Vaccinations received | |||
| None | 1 (0.5) | NA | NA |
| 2 doses | 140 (73) | 50 (51) | NA |
| 3 doses | 51 (27) | 49 (49) | 34 (100) |
Abbreviations: Ig, immunoglobulin; NA, not applicable.
aPost-vaccine: after at least 1 dose.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
